While SomaScan is the company's main source of revenue, it continues to develop its Dx business and will launch its first test in the second half of 2016.
Researchers from Protagen, Targos, and elsewhere have identified autoantibody biomarkers specific to patients diagnosed with prostate cancer.
The Belgian cancer diagnostics firm will provide the lab with access to its OncoDeep DX Plus and Clinical Plus services.
In early experiments, the method's raw single pass error rate was approximately 2 percent for a single target and up to 4 percent for a mixture of 10 targets.
With data from the CanPREDDICT study, the partners will develop a test to predict the rate of disease progression in patients with chronic kidney disease.
In Science this week: Neanderthal-derived DNA linked to modern ailments, and more.
Japan needs to catch up on its gene-editing research efforts, the Japan News writes.
Hundreds of people have signed an online petition calling for zero tolerance to sexual harassment in the sciences.
Jeff Huber, former Google X senior vice president, joins Grail as its CEO.
This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.